{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:57:58Z","timestamp":1789095478812,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.reuma.2017.07.020","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T18:46:07Z","timestamp":1504291567000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis"],"prefix":"10.1016","volume":"15","author":[{"given":"Roberto","family":"Alfaro-Lara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector Fabricio","family":"Espinosa-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Alejandro","family":"Arce-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2017.07.020_bib0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3899\/jrheum.100951","article-title":"Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology","volume":"86","author":"Pel\u00e1ez-Ballestas","year":"2011","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.reuma.2017.07.020_bib0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/berh.2000.0124","article-title":"What is the natural history of rheumatoid arthritis?","volume":"15","author":"Ollier","year":"2001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0215","first-page":"S72","article-title":"Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis","volume":"73","author":"Furneri","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0220","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9343(01)00872-5","article-title":"Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies","volume":"111","author":"Lard","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.reuma.2017.07.020_bib0225","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reuma.2017.07.020_bib0230","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2017.07.020_bib0235","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.reuma.2013.10.006","article-title":"Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis","volume":"10","author":"Cardiel","year":"2014","journal-title":"Reumatol Clin"},{"issue":"Suppl. 31","key":"10.1016\/j.reuma.2017.07.020_bib0240","first-page":"S179","article-title":"Methotrexate as the \u201canchor drug\u201d for the treatment of early rheumatoid arthritis","volume":"21","author":"Pincus","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.reuma.2017.07.020_bib0250","first-page":"S9","article-title":"Update on methotrexate as the anchor drug for rheumatoid arthritis","volume":"71","author":"Pincus","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"key":"10.1016\/j.reuma.2017.07.020_bib0255","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoekstra","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2017.07.020_bib0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","article-title":"The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse reactions","volume":"44","author":"Kinder","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2017.07.020_bib0265","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2017.07.020_bib0270","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/qjmed\/94.6.309","article-title":"Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice","volume":"94","author":"Grove","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.reuma.2017.07.020_bib0275","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.mayocp.2012.03.011","article-title":"My treatment approach to rheumatoid arthritis","volume":"87","author":"Davis","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.reuma.2017.07.020_bib0280","first-page":"404","article-title":"Is there a rationale to using leflunomide in early rheumatoid arthritis?","volume":"23","author":"Dayer","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0285","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/BOR.0b013e328344fddb","article-title":"Update 2011: leflunomide in rheumatoid arthritis \u2013 strengths and weaknesses","volume":"23","author":"Behrens","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0290","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/BOR.0b013e328344f2e4","article-title":"Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?","volume":"23","author":"Singer","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0295","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/art.27358","article-title":"Birth outcomes in women have taken leflunomide during pregnancy","volume":"62","author":"Chambers","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.07.020_bib0300","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.07.020_bib0305","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/kel074","article-title":"The perception of rheumatoid arthritis core set measures by rheumatologist. Results of a survey","volume":"45","author":"Aletaha","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2017.07.020_bib0310","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.reuma.2017.07.020_bib0315","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.reuma.2012.03.013","article-title":"Eficacia de leflunomida 100mg semanales comparado con dosis bajas de metotrexate en pacientes con artritis reumatoide activa. Estudio cl\u00ednico doble ciego aleatorizado","volume":"8","author":"Jaimes-Hern\u00e1ndez","year":"2012","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2017.07.020_bib0320","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/s10165-010-0405-4","article-title":"Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients","volume":"21","author":"Ishaq","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0325","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2017.07.020_bib0330","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.07.020_bib0335","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.reuma.2017.07.020_bib0340","first-page":"S155","article-title":"Efficacy of leflunomide vs placebo vs methotrexate in early and late rheumatoid arthritis","volume":"41","author":"Moreland","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.07.020_bib0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.reuma.2017.07.020_bib0350","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/1529-0131(199909)42:9<1870::AID-ANR11>3.0.CO;2-D","article-title":"Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis","volume":"42","author":"Strand","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.07.020_bib0355","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","article-title":"Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis","volume":"43","author":"Sharp","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.07.020_bib0360","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U","volume":"43","author":"Tugwell","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2017.07.020_bib0365","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2017.07.020_bib0370","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/157339708786263951","article-title":"Measures of disease activity in rheumatoid arthritis: a clinician's guide","volume":"4","author":"Ringold","year":"2008","journal-title":"Curr Rheumatol Rev"},{"issue":"Suppl. 39","key":"10.1016\/j.reuma.2017.07.020_bib0375","first-page":"S109","article-title":"The American College of Rheumatology (ACR) core set and derivative \u201cpatient only\u201d indices to assess rheumatoid arthritis","volume":"23","author":"Pincus","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0380","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/ard.59.12.966","article-title":"Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis","volume":"59","author":"Verhoeven","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2017.07.020_bib0385","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/MLR.0b013e318041384c","article-title":"Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis","volume":"45","author":"Grijalva","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.reuma.2017.07.020_bib0390","first-page":"1182","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"30","author":"Osiri","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2017.07.020_bib0395","first-page":"CD002047","article-title":"Leflunomide for treating rheumatoid arthritis","volume":"1","author":"Osiri","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reuma.2017.07.020_bib0400","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.60.10.913","article-title":"Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine","volume":"60","author":"Scott","year":"2001","journal-title":"Ann Rheum Dis"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X17301961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X17301961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T11:53:40Z","timestamp":1556106820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X17301961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1699258X17301961"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2017.07.020","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2017.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}